May 26, 2026

The Manager – Listing
BSE Limited
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Please find enclosed the press release for the quarter and financial year ended March 31, 2026

Thanking you,

For **AstraZeneca Pharma India Limited**

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.05.26 19:20:29 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Press release

AstraZeneca Pharma India Limited marks consistent 33% growth as the Company announces its annual results for FY 2025-2026

- *Total Revenue reached INR. 22,755.8 Mn in the FY 2025-26*
- *11 regulatory approvals for medicines and indications in FY 2025-26, reinforcing leadership across therapy areas and accelerating the delivery of innovative medicines across India*

Bangalore, 26 May 2026: AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its full-year results for the financial year (FY) ended 31 March 2026. The Company maintained strong momentum during the year and delivered an 33% year-on-year growth in total revenue, reflecting sustained performance across its therapy areas and continued progress in bringing innovative medicines to patients in India.

Financial Performance Summary:

(Value in INR Mn)

Summary	Q4 (Jan- Mar '26)	Full FY Apr '25- Mar '26
Total revenue from Operations	5,786.1	22,755.8
Profit before exceptional item and tax	592.2	2,574.5
Profit after exceptional item and tax	448.8	1,875.2

Summary		Full FY Apr '25- Mar '26
TA-wise performance	**Oncology**	16,100.9
	Biopharmaceuticals (CVRM, R&I and V&I)	5,243.2
	Rare Disease	214.6

During FY 2025-26, AstraZeneca India recorded total revenue from operations of INR 22,755.8 Mn, supported by continued growth in Oncology and Biopharmaceuticals, as well as progress in Rare Disease. The year was also marked by 11 new regulatory approvals for medicines and indications, underscoring the Company's commitment to scientific innovation, bringing them to the country at an accelerated pace and its focus on addressing unmet patient needs across India.

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said: "FY 2025-26 was a year of strong and consistent growth for AstraZeneca India, underpinned by the resilience of our business, the strength of our science-led portfolio, and disciplined execution across the organisation. Our performance reflects not only commercial momentum, but also our continued commitment to creating sustainable value through innovation, responsible growth, and meaningful impact for patients, society, and the planet."

Praveen Rao Akkinepally, Managing Director, AstraZeneca India, added: "At AstraZeneca, science is at the heart of everything we do. Our FY 2025-26 performance reflects the progress we are making, accelerating the delivery of innovative medicines across key therapy areas and advancing our ambition to transform patient outcomes in India. With a strong pipeline and a clear sense of purpose, we remain focused on addressing unmet medical needs, advancing the healthcare ecosystem, and creating long-term impact through science-led innovation."

Key milestones: During FY '25-26, the Company achieved several important regulatory and business milestones that strengthened its portfolio and expanded patient access to innovative therapies in India.

- **Durvalumab – endometrial cancer**: Received regulatory approval from CDSCO to import for sale and distribution of Durvalumab solution for infusion for two additional indications. Durvalumab in combination with carboplatin and paclitaxel is now indicated for first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy; followed by maintenance treatment with Durvalumab in combination with Olaparib in endometrial cancer that is *pMMR*.
- **Durvalumab – muscle invasive bladder cancer (MIBC)**: Received regulatory approval from CDSCO to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml for an additional indication as adjuvant treatment following radical cystectomy for adult patients with MIBC.
- **Eculizumab – rare diseases**: Launched **Eculizumab**, the first anti-complement therapy approved in India by CDSCO for the treatment of *atypical Haemolytic Uremic Syndrome (aHUS)* and *Paroxysmal Nocturnal Hemoglobinuria (PNH)*, marking a significant milestone in rare diseases.
- **Osimertinib – NSCLC**: Received regulatory approval to import for sale and distribution of Osimertinib tablets for an additional indication in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC with *EGFR exon 19 deletions or exon 21 (L858R)* substitution mutations.

- **Trastuzumab deruxtecan – HER2 spectrum expansion**: Received regulatory approval from CDSCO to import for sale and distribution of **trastuzumab deruxtecan** for an additional indication in *HER2-low* and *HER2-ultralow* metastatic breast cancer patients who have received at least one endocrine therapy in the metastatic setting.
- **Osimertinib – NSCLC (stage III, monotherapy)**: Gained CDSCO regulatory approval for an additional indication of **Osimertinib** as monotherapy for import for sale and distribution for the treatment of patients with locally advanced, unresectable (stage III) NSCLC with *EGFR exon 19 deletions or exon 21 (L858R)* substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy.
- **Benralizumab – EGPA**: Received regulatory approval from CDSCO to import for sale and distribution of **Benralizumab** for an additional indication as an add-on treatment for adult patients with relapsing or refractory *eosinophilic granulomatosis with polyangiitis (EGPA)*.
- **Sodium Zirconium Cyclosilicate (5g/10g)** – Hyperkalaemia: Received CDSCO permission for import and sale in India. The therapy is indicated for the management of hyperkalaemia in adults, particularly associated with cardiovascular, renal, and metabolic conditions *(in partnership with Sun Pharma)*.
- **Durvalumab – Gastric Cancer**: Received regulatory approval from CDSCO in January 2026 for Durvalumab in combination with FLOT chemotherapy as perioperative treatment for adults with resectable gastric or gastroesophageal junction adenocarcinoma, based on the MATTERHORN trial demonstrating improved event-free survival.
- **Durvalumab – Liver Cancer:** Durvalumab plus tremelimumab received expanded regulatory approval or recommendation from CDSCO in March 2026 for first-line treatment of unresectable hepatocellular carcinoma, following the HIMALAYA trial results showing significant overall survival benefit over sorafenib.

Recognitions:

- Pharma Company of the Year at ET RePharma Awards
- Medical Excellence Award for Rare Disease at OPPI India
- Recognised as Top Employer India 2025
- Marketing Excellence Award for Hyperkalaemia & Kidney Care, Biopharmaceuticals at OPPI India
- OPPI Medical Excellence Award 2025 for Medical Affairs, Regulatory Excellence, and Clinical Trials.
- 1st Place in 2025 SAS Customer Recognition Awards for innovative use of Real-World Data in clinical trials.
- ET HRWorld EX Awards 2025: AstraZeneca Pharma India awarded for Exceptional Employee Experience (Large Scale), recognizing our progress in I&D.
- Excellence in Precision Biopharma Solutions at the VOH National Healthcare Awards 2025.

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in

over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: https://www.astrazeneca.in/ or follow us on LinkedIn: AstraZeneca India.

Media contact: M Sindhu: sindhu.manivannan@astrazeneca.com